SLDB Q2 2021 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$581M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M

Gross Profit

$4M100.0% margin

Operating Income

-$19M-519.9% margin

Net Income

-$19M-520.2% margin

EPS (Diluted)

$-2.50

QoQ Revenue Growth

+7.8%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$266M

Total Liabilities

$28M

Stockholders' Equity

$238M

Cash & Equivalents

$201M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$0	—
Gross Profit	$4M	$0	—
Operating Income	-$19M	-$19M	+1.5%
Net Income	-$19M	-$19M	+1.5%